Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Georg M. Haag"'
Autor:
Tim Schmäche, Juliane Fohgrub, Anna Klimova, Karin Laaber, Stephan Drukewitz, Felix Merboth, Alexander Hennig, Therese Seidlitz, Friederike Herbst, Franziska Baenke, Anne-Marlen Ada, Thomas Groß, Carina Wenzel, Claudia R. Ball, Christian Praetorius, Thomas Schmidt, Barbara Ringelband-Schilling, Ronald Koschny, Albrecht Stenzinger, Ingo Roeder, Dirk Jaeger, Sebastian Zeissig, Thilo Welsch, Daniela Aust, Hanno Glimm, Gunnar Folprecht, Jürgen Weitz, Georg M. Haag, Daniel E. Stange
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-8 (2024)
Abstract Background and aims This study sought to determine the value of patient-derived organoids (PDOs) from esophago-gastric adenocarcinoma (EGC) for response prediction to neoadjuvant chemotherapy (neoCTx). Methods Endoscopic biopsies of patients
Externí odkaz:
https://doaj.org/article/ef3c4b197b1249f6b014c0fc293e9167
Autor:
Sabine Schiefer, Nerma Crnovrsanin, Eva Kalkum, Johannes A. Vey, Henrik Nienhüser, Ingmar F. Rompen, Georg M. Haag, Beat Müller-Stich, Franck Billmann, Thomas Schmidt, Pascal Probst, Rosa Klotz, Leila Sisic
Publikováno v:
Frontiers in Surgery, Vol 11 (2024)
BackgroundThe impact of neoadjuvant chemotherapy (nCTX) on survival and tumor response in patients with esophagogastric signet ring cell carcinoma (SRCC) is still controversial.MethodsTwo independent reviewers performed a systematic literature search
Externí odkaz:
https://doaj.org/article/82f1f08516b243958d32679187953bd7
Autor:
Ralf-Dieter Hofheinz, Kirsten Merx, Georg M. Haag, Christoph Springfeld, Thomas Ettrich, Kersten Borchert, Albrecht Kretzschmar, Christian Teschendorf, Gabriele Siegler, Matthias P. Ebert, Eray Goekkurt, Rolf Mahlberg, Nils Homann, Daniel Pink, Wolf Bechstein, Peter Reichardt, Hagen Flach, Timo Gaiser, Achim Battmann, Fuat S. Oduncu, Maria Loose, Disorn Sookthai, Claudia Pauligk, Thorsten O. Göetze, Salah-Eddin Al-Batran
Publikováno v:
Journal of Clinical Oncology. 40:3750-3761
PURPOSE High pathologic complete response (pCR) rates and comparably good survival data were seen in a phase II trial combining perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy with trastuzumab for resectable, es
Autor:
Thomas, Walle, Sunanjay, Bajaj, Joscha A, Kraske, Thomas, Rösner, Christiane S, Cussigh, Katharina A, Kälber, Lisa Jasmin, Müller, Sophia Boyoung, Strobel, Jana, Burghaus, Stefan M, Kallenberger, Christoph K, Stein-Thöringer, Maximilian, Jenzer, Antonia, Schubert, Steffen, Kahle, Anja, Williams, Birgit, Hoyler, Lin, Zielske, Renate, Skatula, Stefanie, Sawall, Mathias F, Leber, Russell Z, Kunes, Johannes, Krisam, Carlo, Fremd, Andreas, Schneeweiss, Jürgen, Krauss, Leonidas, Apostolidis, Anne Katrin, Berger, Georg M, Haag, Stefanie, Zschäbitz, Niels, Halama, Christoph, Springfeld, Romy, Kirsten, Jessica C, Hassel, Dirk, Jäger
Publikováno v:
Nature cancer. 3(9)
Patients with cancer frequently receive immune-checkpoint inhibitors (ICIs), which may modulate immune responses to COVID-19 vaccines. Recently, cytokine release syndrome (CRS) was observed in a patient with cancer who received BTN162b2 vaccination u